The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

This study is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.

Inclusion Criteria:

• BMI 25.0-50.0 kg/m²
• Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.

Exclusion Criteria:

• Women who are still having menses
• Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
• Persons who consume moderate-large amounts of caffeine daily (>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
• Unstable weight (>3% change during the last 2 months before entering the study)

From enrollment until the end of follow up after 16 weeks of supplementation

We used the adverse events definitions defined by ClinicalTrials.gov